Terumo (OTCMKTS:TRUMY) Stock Price Passes Below 50-Day Moving Average - What's Next?

Key Points

• Terumo Corp.'s stock price has fallen below its 50-day moving average, trading as low as $16.06, and closing at $16.30.
• The company reported earnings per share of $0.20, exceeding the estimate of $0.17, though revenue of $1.76 billion fell short of projections of $1.80 billion.
• Terumo has a market cap of $24.13 billion and maintains a low debt-to-equity ratio of 0.07, indicating financial stability.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $17.62 and traded as low as $16.06. Terumo shares last traded at $16.30, with a volume of 127,952 shares trading hands.

Terumo Stock Performance

The company has a market cap of $24.13 billion, a PE ratio of 28.60 and a beta of 0.79. The firm's fifty day moving average is $17.62 and its 200 day moving average is $18.12. The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07.

Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.17 by $0.03. The company had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.80 billion. Terumo had a net margin of 12.09% and a return on equity of 9.19%.

Terumo Company Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.